Furmonertinib 160mg

DRUG2 trials

Sponsors

Allist Pharmaceuticals, Inc.

Conditions

NSCLC

Phase 1

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

CompletedNCT04858958

Allist Pharmaceuticals, Inc.NSCLC

Start: 2020-08-10End: 2025-06-25Updated: 2026-08-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

WithdrawnNCT04958967

Allist Pharmaceuticals, Inc.NSCLC

Start: 2021-10-01End: 2022-08-01Updated: 2025-03-14

Related Papers

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

2023-04-0121 citations